The going rate to buy a voucher for a faster US FDA application review is about $100m, but the France-headquartered firm received considerably more from an unnamed big pharma.

The going rate to buy a voucher that speeds up a regulatory review in the US is about $100m but the France-headquartered firm has managed to get considerably more from an unnamed big pharma.

The Paris-based group has inked five external deals already this year, this time paying $111m to get access internationally to Day One Biopharmaceuticals' Ojemda for refractory pediatric low-grade glioma.

Deal Snapshot: Ipsen has entered into a global licensing agreement with Foreseen Biotechnology potentially worth up to $1.03bn, its second antibody-drug conjugate tie-up this year, a few months after unveiling a partnership with Sutro.